News

Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for ...
Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD
Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD Injection 8 mg. The sBLA seeks ...
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment ...